Cigna Specialty Care Options programs: Changes to the drug list
AI Summary
Cigna has expanded its Specialty Care Options programs to include additional specialty medical injectables that require site-of-care review to determine if lower-intensity settings are clinically appropriate. Most hemophilia clotting factors become effective July 1, 2026, while some immune globulin and oncology medications have earlier effective dates.
Action Required
By March 9, 2026: Billing team must ensure prior authorization is obtained for QIVIGV immune globulin treatments. By March 23, 2026: Add prior auth requirement for LOARGYS. By April 1, 2026: Add AUKELSO to prior auth list. By July 1, 2026: Update billing system to require prior authorization for all hemophilia clotting factors and BLINCYTO listed in the policy before administering in outpatient hospital settings. Review Cigna's Specialty Care Options drug list regularly as it changes frequently.
Plan Types
Commercial
Specialties
hematology, oncology, general-practice, internal-medicine